Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Optinose Inc (OPTN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 485,984
  • Shares Outstanding, K 41,220
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,900 K
  • 36-Month Beta N/A
  • Price/Sales 560.49
  • Price/Cash Flow N/A
  • Price/Book 2.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.68
  • Number of Estimates 2
  • High Estimate -0.64
  • Low Estimate -0.71
  • Prior Year -4.23
  • Growth Rate Est. (year over year) +83.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.78 +15.34%
on 10/11/18
14.20 -20.56%
on 09/19/18
-2.37 (-17.36%)
since 09/18/18
3-Month
9.78 +15.34%
on 10/11/18
27.28 -58.65%
on 07/19/18
-15.67 (-58.14%)
since 07/18/18
52-Week
9.78 +15.34%
on 10/11/18
30.00 -62.40%
on 07/09/18
-7.86 (-41.07%)
since 10/18/17

Most Recent Stories

More News
Optinose to Highlight Data at Two Upcoming Scientific Meetings

YARDLEY, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

OPTN : 11.35 (-3.73%)
Optinose to Present at the 2018 Cantor Global Healthcare Conference

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present...

OPTN : 11.35 (-3.73%)
INVESTOR ALERT: Investigation of OptiNose Announced by Holzer & Holzer

Holzer & Holzer, LLC is investigating whether OptiNose, Inc. ("OptiNose" or the "Company") (NASDAQ: OPTN) complied with the federal securities laws. On August 14, 2018, OptiNose issued financial...

OPTN : 11.35 (-3.73%)
OptiNose: 2Q Earnings Snapshot

YARDLEY, Pa. (AP) _ OptiNose Inc. (OPTN) on Tuesday reported a loss of $24.6 million in its second quarter.

OPTN : 11.35 (-3.73%)
Optinose Reports Second Quarter 2018 Financial Results and Recent Operational Highlights

Company reports second quarter net product sales of $1.3 million and that more than 2,600 physicians have prescribed XHANCE since launch

OPTN : 11.35 (-3.73%)
Optinose to Report Second Quarter 2018 Financial Results and Corporate Updates on August 14, 2018

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the second...

OPTN : 11.35 (-3.73%)
Option Care Announces Expansion into Louisiana

Option Care Enterprises, Inc. ("Option Care"), the nation's largest provider of home and alternate treatment site infusion therapy services, is expanding patient access to care with...

OPTN : 11.35 (-3.73%)
New Study of Option Care Data Suggests Improved Survival for Heart Failure Patients Receiving Home Infusion of Inotropic Therapy When Coupled with Guideline-Directed Medical Therapy

Survival may improve when advanced heart failure patients receiving home infusion of inotropic therapy are also receiving guideline-directed care, suggest results of a large study recently...

OPTN : 11.35 (-3.73%)
OptiNose, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 14, 2018 / OptiNose, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 8:00 AM Eastern Time.

OPTN : 11.35 (-3.73%)
OptiNose: 1Q Earnings Snapshot

YARDLEY, Pa. (AP) _ OptiNose Inc. (OPTN) on Monday reported a loss of $30.6 million in its first quarter.

OPTN : 11.35 (-3.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade OPTN with:

Business Summary

OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and...

See More

Key Turning Points

2nd Resistance Point 12.62
1st Resistance Point 12.21
Last Price 11.35
1st Support Level 11.16
2nd Support Level 10.52

See More

52-Week High 30.00
Fibonacci 61.8% 22.28
Fibonacci 50% 19.89
Fibonacci 38.2% 17.50
Last Price 11.35
52-Week Low 9.78

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar